An anti-COVID-19 therapeutic drug developed by DRDO called drug2-deoxy-D-glucose (2-DG) has been given emergency approval by the Drug Controller General of India (DCGI) for Coronavirus patients in the country. The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
In 2-DG arm, significantly higher proportion of patients improved symptomatically and became free from supplemental oxygen dependence (42% vs 31%) by day-3 in comparison to SOC, indicating an early relief from oxygen therapy/dependence. The drug comes in the form of a powder in a sachet & is supposed to be dissolved in water.
Important takeaways for all competitive exams:
India is set to consider to making the Advanced Emergency Braking Systems (AEBS) mandatory in…
Indian Space Research Organization (ISRO), the NVS-03 navigation satellite will be launched on October 30ht…
The Ajanta Caves, which are located inside a horseshoe-shaped gorge in Maharashtra, contain some of…
The Ministry of Communications, from the Department of Telecommunications (DoT) has notified the Telecommunications (Regulatory…
The 33rd edition of the bilateral maritime exercise between Singapore and India (SIMBEX-2026) commenced on…
Venerable folk artist Devadas Chimakode has won the prestigious annual honorary award of Karnataka Janapada…